Merck & Co., Inc. won’t be the first to deliver an antiviral drug or a vaccine to treat or prevent COVID-19, but the company revealed progress during its third quarter earnings call on an antiviral and two vaccine candidates that it thinks will be an improvement on the efforts other companies have put forth against the novel coronavirus.
Merck & Co.’s Q3 revenue jumped 1% year-over-year to $12.55bn, beating analyst consensus of $12.16bn, as growth from Keytruda (pembrolizumab) and other products offset weakness in the company’s vaccine business, which is beginning to recover from declining sales due to the general drop in routine doctor visits as patients seek to avoid exposure to COVID-19
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?